---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062007"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:24:27.602385+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eledon reports Q3 net loss $10.3M ($0.35/sh); cash $59.6M; advances tegoprubart trials

## Summary
- Net loss of $10.3M ($0.35 per share) vs $10.5M ($0.73) YoY; R&D spend $7.9M.
- Cash & short-term investments $59.6M as of Sept 30, 2023, up from $56.4M at Dec 31, 2022.
- Phase 1b data: tegoprubart prevented kidney transplant rejection; mean eGFR >70 at all post-Day 90 timepoints.
- First participant dosed in Phase 2 BESTOW trial for kidney transplant rejection; enrollment completion targeted end of 2024.
- Tegoprubart used in second-ever pig-to-human heart transplant; appointed new CMO (Eliezer Katz) and two board members.

## SEC filing metadata
- accession: 0000950170-23-062007
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/0000950170-23-062007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/eldn-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062007
- JSON: https://secwatch.observer/filing/0000950170-23-062007.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062007.txt

## Key facts
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income net loss of $10.3 million, or $0.35 per share, EPS $0.35 per share.
  - Period: three months ended September 30, 2023
  - Net income: net loss of $10.3 million, or $0.35 per share
  - EPS: $0.35 per share
  - Result: reported results
  source text: The company reported a net loss of $10.3 million, or $0.35 per share, for the three months ended September 30, 2023, compared to a net loss of $10.5 million, or $0.73 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/0000950170-23-062007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.